Navigation Links
Blunt: 'New' SCHIP Bill Addresses None of the Problems With the 'Old'
Date:10/25/2007

WASHINGTON, Oct. 25 /PRNewswire-USNewswire/ -- House Republican Whip Roy Blunt (Mo.) issued the following statement today after Democrats attempted once again to use a children's health program created by Republicans to expand taxpayer-funded care to people who are neither children nor poor -- and in some cases, not even in this country legally:

"Many of us had hoped the majority would take our concerns to heart and come back with an SCHIP bill that extends quality health care to poor kids first. Instead, we got a hastily assembled bill that few of us were given an adequate chance to read -- resulting in a final product that addresses none of the serious issues that have plagued the Democrats' plan from the outset.

"The majority insists this is a bill about children's health, but the plan we have before us would allow adults to remain eligible. The majority insists the bill was crafted with the interests of poor kids in mind, but it was written in a way that ensures families making as much as $73,000 remain on the rolls. And the majority insists that those here illegally would no longer be in a position to collect taxpayer-funded benefits, but the Social Security Administration has been clear that they will.

"If this bill truly represented a genuine compromise, we would've been given more than a couple hours to read it. As it is, we voted on legislation today that will never become law. And because of that, we missed yet another opportunity to send the president a bill that's committed to insuring poor kids first."


'/>"/>
SOURCE House Republican Whip Roy Blunt
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. New Drug in Diabetic Neuropathy
2. New Drug for Bronchial Asthma
3. Bad News for Short People
4. NEW ROBOTIC SURGERY ARM APPROVED BY FDA
5. New hope on the Horizon for People Wishing to Quit Smoking
6. Potential New Cancer Gene Identified
7. New CPR Guidelines issued by Heart Association
8. Genetic Dentistry: Your Dentist may be able to grow you a new set of Teeth.
9. New Way to "See" Genes, Evaluate Effectiveness of Gene Therapies Discovered
10. Feeding channel created by malaria parasite - a new target for malaria treatments
11. Kidney Stones - Interesting New Research implicates bacteria as its cause
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... The report, “Feed Palatability Enhancers & ... (Swine, Poultry, Cattle, Pets, Aquaculture, and Others) - Global ... feed palatability enhancers & modifiers market with an analysis ... value, of types of feed flavors, sweeteners, and text ... figures spread through 275 pages and in-depth TOC on ...
(Date:7/24/2014)... increases your risk of death, but recessions decrease ... While previous studies of individuals have shown that ... mortality rate, more comprehensive studies have shown, unexpectedly, ... increase. Researchers from Drexel University and the University ... better understand these seemingly contradictory findings. , Using ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 While healthcare ... in providing quality interpretation services to non-English speakers within ... down. According to Common Sense Advisory, the language ... to $2.3 billion in 2016 (1); additionally, officials at ... to shift over to video remote interpreting ...
(Date:7/24/2014)... known as neonicotinoids, were found commonly in streams ... study. This is the first broad-scale investigation of ... one of the first conducted within the United ... of insect pests, use of neonicotinoid insecticides has ... United States, particularly in the Midwest. The ...
(Date:7/24/2014)... Dr. Kwame Bawuah Edusei, a diplomat, entrepreneur, medical ... to the youth to persevere in their endeavors to ... the youth to stay away from social vices and ... will afford you the opportunity of acquiring life surviving ... in your career path.” Professionals in the fields of ...
Breaking Medicine News(10 mins):Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 2Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 3Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 4Health News:Joblessness could kill you, but recessions could be good for your health 2Health News:Joblessness could kill you, but recessions could be good for your health 3Health News:Stratus Video Interpreting Predicts $1 Billion Market Shift to Video Remote Interpreting by 2016 as Court and Healthcare Systems Heed Cost-Effectiveness 2Health News:Stratus Video Interpreting Predicts $1 Billion Market Shift to Video Remote Interpreting by 2016 as Court and Healthcare Systems Heed Cost-Effectiveness 3Health News:Stratus Video Interpreting Predicts $1 Billion Market Shift to Video Remote Interpreting by 2016 as Court and Healthcare Systems Heed Cost-Effectiveness 4Health News:Corn & soy insecticides similar to nicotine found widespread in Midwest rivers -- USGS news 2Health News:Youth and Professionals Interact at Washington Metro Area Career Workshop Hosted by the Edusei Foundation 2
... aid in understanding ADD and more , FRIDAY, Aug. 28 ... a crowd, it appears that your "mind,s eye" acts like ... until you find the right person. , Researchers from the ... as they searched for a specific tilted, colored bar among ...
... 28 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE: ... announced today that,the Beijing Public Health Bureau has selected ... Sinovac,s seasonal influenza vaccine, for,the benefit of the citizens ... process for the purchase of flu vaccines and,corresponding services ...
... , HARBIN, China, Aug. 28 ... Medical" or "the Company") (Nasdaq: CSKI ), ... People,s Republic of China ("PRC"), today announced that the,Company,s ... Thursday,September 24, 2009 at Harbin Shen Te Hotel which ...
... ... , ... (PRWEB) August 28, 2009 -- Promising cancer research treatment breakthrough seeks funding for corroboration., ... CHAI Foundation , a small 501(c)(3) non-profit medical research organization seeking to find ...
... , TOKYO, Aug. 28 ALOKA CO., ... generation of compact color ultrasound systems. This new multi-purpose system, ... fully upgradable and easy to use. , , ... ProSound Alpha 10 and Alpha 7, the ProSound Alpha 6 ...
... , TOSU, Saga, Japan and MIAMI, Aug. ... Inc. today announced the completion of their acquisition of Noven Pharmaceuticals, ... Inc., a wholly owned subsidiary of Hisamitsu U.S., Inc., with and ... the Agreement and Plan of Merger among the companies, at the ...
Cached Medicine News:Health News:Brain May Use Its 'Mind's Eye' to Control Chaos 2Health News:Sinovac Wins Beijing Public Health Bureau's Bid to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens 2Health News:Sinovac Wins Beijing Public Health Bureau's Bid to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens 3Health News:China Sky One Medical, Inc. to Hold Annual Meeting of Shareholders on September 24, 2009 2Health News:China Sky One Medical, Inc. to Hold Annual Meeting of Shareholders on September 24, 2009 3Health News:Promising Cancer Research Treatment Breakthrough Seeks Funding for Corroboration of Results 2Health News:ALOKA Announces New ProSound Alpha Series Ultrasound System 2Health News:ALOKA Announces New ProSound Alpha Series Ultrasound System 3Health News:Hisamitsu Pharmaceutical Completes Acquisition of Noven Pharmaceuticals 2
(Date:7/24/2014)... DIEGO , July 24, 2014 ... industry leader in bioactive lipid-targeted therapeutics, reported interim ... where ASONEP™ is being investigated as a treatment ... that have failed at least one therapy involving ... no more than one mTOR inhibitor (e.g., Afinitor®/everolimus), ...
(Date:7/24/2014)... N.J., July 24, 2014 , Revenues ... year , Adjusted diluted EPS from continuing operations of ... EPS from continuing operations of $0.92, 7% below prior year ... versus prior year , Full year 2014 revenues now ... to 4% previously , Full year 2014 adjusted diluted ...
(Date:7/24/2014)... HIGHLIGHTS:Q2 2014 Results (all percentage changes ... sales increased 3% to $701 million.  Sales grew organically by ... percentage point to sales growth. , By business unit, ... and 1% in SAFC Commercial. , Reported diluted EPS ... of 13%.  Adjusted diluted EPS in Q2 2014 was also ...
Breaking Medicine Technology:Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 2Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 3Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 4Quest Diagnostics Reports Second Quarter 2014 Financial Results 2Quest Diagnostics Reports Second Quarter 2014 Financial Results 3Quest Diagnostics Reports Second Quarter 2014 Financial Results 4Quest Diagnostics Reports Second Quarter 2014 Financial Results 5Quest Diagnostics Reports Second Quarter 2014 Financial Results 6Quest Diagnostics Reports Second Quarter 2014 Financial Results 7Quest Diagnostics Reports Second Quarter 2014 Financial Results 8Quest Diagnostics Reports Second Quarter 2014 Financial Results 9Quest Diagnostics Reports Second Quarter 2014 Financial Results 10Quest Diagnostics Reports Second Quarter 2014 Financial Results 11Quest Diagnostics Reports Second Quarter 2014 Financial Results 12Quest Diagnostics Reports Second Quarter 2014 Financial Results 13Quest Diagnostics Reports Second Quarter 2014 Financial Results 14Quest Diagnostics Reports Second Quarter 2014 Financial Results 15Quest Diagnostics Reports Second Quarter 2014 Financial Results 16Quest Diagnostics Reports Second Quarter 2014 Financial Results 17Quest Diagnostics Reports Second Quarter 2014 Financial Results 18Quest Diagnostics Reports Second Quarter 2014 Financial Results 19Quest Diagnostics Reports Second Quarter 2014 Financial Results 20Quest Diagnostics Reports Second Quarter 2014 Financial Results 21Quest Diagnostics Reports Second Quarter 2014 Financial Results 22Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 2Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 3Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 4Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 5Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 6Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 7Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 8Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 9Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 10Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 11Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 12
... budget pressures, countries around the world are making ... lure the biopharmaceutical research sector away from the ... Technology Partnership Practice. The study, commissioned ... (PhRMA), further found that while many countries are ...
...   Accuray Incorporated (Nasdaq: ARAY ), ... of Richard Pettingill, LFACHE as a member of the ... Richard Pettingill,s career as a healthcare executive ... variety of prominent organizations. Most recently, Pettingill, who is ...
Cached Medicine Technology:New Study Details Foreign Efforts To Lure Biopharmaceutical Companies 2New Study Details Foreign Efforts To Lure Biopharmaceutical Companies 3Accuray Appoints Richard Pettingill, LFACHE to Board of Directors 2Accuray Appoints Richard Pettingill, LFACHE to Board of Directors 3
Ideal for use with thinner casting materials such as polyester or fiberglass. Conforms to any casting material....
This lightweight cast boot features a sturdy canvas upper. The three layer EVA rocker outsole provides excellent shock absorption....
... assay for the qualitative and ... to Gliadin in human serum. ... be used as an aid ... disorders, mainly Coeliac Disease. This ...
... Myeloperoxidase IgG ELISA test system is intended ... IgG-class antibody to myeloperoxidase in human serum. ... used as an aid in the diagnosis ... elevated levels of anti-neutrophil cytoplasmic antibodies (ANCA). ...
Medicine Products: